Stopping Onabotulinum Treatment after the First Two Cycles Might Not Be Justified: Results of a Real-life Monocentric Prospective Study in Chronic Migraine.

Sarchielli, Paola; Romoli, Michele; Corbelli, Ilenia; Bernetti, Laura; Verzina, Angela; Brahimi, Elona; Eusebi, Paolo; Caproni, Stefano; Calabresi, Paolo

Sarchielli, Paola; Romoli, Michele; Corbelli, Ilenia; Bernetti, Laura; Verzina, Angela; Brahimi, Elona; Eusebi, Paolo; Caproni, Stefano; Calabresi, Paolo.

Afiliação

Sarchielli P; Neurology Clinic, University of Perugia-Perugia General Hospital, Perugia, Italy.
Romoli M; Neurology Clinic, University of Perugia-Perugia General Hospital, Perugia, Italy.
Corbelli I; Neurology Clinic, University of Perugia-Perugia General Hospital, Perugia, Italy.
Bernetti L; Neurology Clinic, University of Perugia-Perugia General Hospital, Perugia, Italy.
Verzina A; Neurology Clinic, University of Perugia-Perugia General Hospital, Perugia, Italy.
Brahimi E; Neurology Clinic, University of Perugia-Perugia General Hospital, Perugia, Italy.
Eusebi P; Regional Health Authority, Public Health Regional Department, Perugia, Italy.
Caproni S; Neurology Clinic, University of Perugia-Perugia General Hospital, Perugia, Italy.
Calabresi P; Neurology Clinic, University of Perugia-Perugia General Hospital, Perugia, Italy.

Front Neurol ; 8: 655, 2017.

Article em En | MEDLINE | ID: mdl-29255444

Palavras-chave

botox; chronic migraine; migraine; migraine treatment; onabotulinum toxin A

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Observational_studies / Prognostic_studies Idioma: En Revista: Front Neurol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Itália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google